A Real-world, Prospective, Multi-center, Open-label, Phase 4 Clinical Study to Evaluate the Safety and Effectiveness of Subcutaneous Injection of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Latest Information Update: 26 May 2026
At a glance
- Drugs Inclisiran (Primary)
- Indications Dyslipidaemias; Hypercholesterolaemia
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 04 May 2026 Actual primary completion date changed from 2 Jan 2026 to 13 Jan 2026.
- 24 Apr 2026 Status changed from active, no longer recruiting to completed.
- 24 Apr 2025 Status changed from recruiting to active, no longer recruiting.